Results 151 to 160 of about 70,337 (231)

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. [PDF]

Oncotarget, 2022
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B.   +17 more
europepmc   +1 more source

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

Curr Breast Cancer Rep
Ray A, Opyrchal M.
europepmc   +1 more source

Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages. [PDF]

Front Immunol, 2021
van Doorn CLR, Steenbergen SAM, Walburg KV, Ottenhoff THM.   +3 more
europepmc   +1 more source

Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol
Rao M, Merrill M, Troxel M, Chiang S, Momeni-Boroujeni A, Hensley ML, Schram AM.   +6 more
europepmc   +1 more source

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. [PDF]

Cochrane Database Syst Rev, 2021
Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M.   +6 more
europepmc   +1 more source

Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Cheng CC, Ma LJ, Pang XM, Huang TS, Wang MF, Xu JY, Wang RQ, Chen X, Sun K, Zhao WX, Yan M, Wang P.   +11 more
europepmc   +1 more source

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. [PDF]

Front Oncol, 2022
Gou R, Li X, Dong H, Hu Y, Liu O, Liu J, Lin B.   +6 more
europepmc   +1 more source

Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review). [PDF]

Oncol Lett
Han Y, Wei L.
europepmc   +1 more source

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. [PDF]

Front Oncol, 2022
Luo J, Ou S, Wei H, Qin X, Jiang Q.
europepmc   +1 more source

Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]

Curr Oncol
Ha HI, Yoon HJ, Song C, Kim ET, Suh DS, Kim KH, Na YJ, Song YJ.   +7 more
europepmc   +1 more source